Pharma BD Deal Intelligence

Pfizer Inc. / Valneva SE (VLA15 collaboration update)

2022 · Co-Development · $363M · Complete

A slow-burn vindication: Pfizer's $95M equity bet on Valneva survived a February 2023 setback that discontinued roughly half the U.S. VALOR participants over site-level GCP violations, before Phase 3 efficacy of 73.2% arrived in 2026.

Outcome grade pending — assessed 5 years post-close.

Full analysis, sources & comparables →

The coverage arc

Jun 22, 2022 BioPharma Dive Bullish

Pfizer expanded its Lyme disease vaccine partnership with Valneva on Wednesday, taking an 8.1% equity stake in the French biotech and restructuring milestones…

Jun 22, 2022 Fierce Pharma Bullish

Pfizer is putting fresh capital into the troubled Lyme disease vaccine space with a 95 million dollar equity investment in Valneva, signaling commitment to…

Jun 23, 2022 BioSpace Bullish

Pfizer is making a fresh equity investment in Valneva worth approximately 90.5 million euros to support advancement of VLA15, the only Lyme disease vaccine…

Source summaries from our enrichment pipeline; follow links for originals.

All 14 sources with sentiment breakdown →

Pfizer and Valneva updated their Lyme disease vaccine collaboration on June 22, 2022: Pfizer made a EUR90.5M (~$95M) equity investment for an 8.1% stake in Valneva, with up to $168M in remaining development/early-commercialization milestones, up to $100M in cumulative sales milestones, and tiered 14%-22% royalties, alongside initiation of the Phase 3 VALOR study (VLA15) in Q3 2022. The program then weathered a major setback: on February 17, 2023 Pfizer discontinued roughly half of the U.S. participants after Good Clinical Practice violations were found at a third-party clinical-trial site operator (not a vaccine safety or adverse-event issue). VALOR continued, and on March 22-23, 2026 Pfizer and Valneva reported strong Phase 3 efficacy for the six-valent OspA-based candidate (now PF-07307405 / LB6V, formerly VLA15): 73.2% efficacy from 28 days post-dose 4 (season 2) and 74.8% from 1 day post-dose 4, with the vaccine well tolerated and no safety concerns identified. Pfizer stated it is planning submissions to regulatory authorities (FDA/EMA). A positive readout materially de-risks what would be the first Lyme disease vaccine since LYMErix was withdrawn in 2002.

Key facts

Disease & market context

Lyme Disease (Prevention)

476K US cases/yr · $1.0B Estimated U.S. Lyme vaccine peak revenue opportunity · ~30,000-40,000 Annual cases formally reported to CDC surveillance

Disease Overview

Lyme disease is the most common vector-borne illness in the United States, caused by Borrelia burgdorferi (and related Borrelia species) and transmitted via Ixodes scapularis (deer tick) and Ixodes pacificus bites. The CDC estimates approximately 476,000 Americans are diagnosed and treated for Lyme disease annually, based on insurance claims data, though only about 30,000-40,000 cases are formally reported through public health surveillance. Geographic concentration is heavy in the Northeast (Connecticut, New York, Pennsylvania, New Jersey, Massachusetts), upper Midwest (Wisconsin, Minnesota), and parts of Northern California, with climate-driven tick range expansion increasing endemic exposure annually. Untreated infection can progress from erythema migrans to disseminated arthritis, carditis, and neuroborreliosis. There is currently no licensed Lyme vaccine on the U.S. market — GSK's LYMErix was withdrawn in 2002 amid weak commercial uptake and class-action concerns despite being safe and effective. The unmet prevention need is acute, the addressable population is large in endemic states, and ACIP/CDC engagement on a successor vaccine is well-established. Pricing precedent for adult travel/recreational vaccines suggests $150-250 per series at WAC.

Competitive Landscape

The Lyme disease vaccine landscape is effectively a single-asset competitive picture. The Pfizer/Valneva VLA15 program is a multivalent recombinant OspA-based vaccine targeting six serotypes covering Borrelia strains relevant in North America and Europe — currently in Phase 3 (VALOR study) and the only candidate in pivotal development. Historical context includes GSK's LYMErix (monovalent OspA), approved by FDA in 1998 and withdrawn voluntarily in 2002 due to commercial underperformance and litigation pressure rather than safety failure. Earlier-stage competitors include MassBiologics' Lyme PrEP monoclonal antibody (anti-OspA mAb passive immunization, Phase 1/2) and academic programs at Yale and Stony Brook exploring alternative antigen approaches. No mRNA Lyme vaccine has progressed publicly into late-stage development. The competitive moat for VLA15 is the combination of pivotal-stage lead time (5-7 years ahead of any competing vaccine candidate), multivalent design covering both U.S. and European serotypes, and the established Pfizer vaccine commercial infrastructure post-COVID. Pricing precedent for adult travel and adult booster vaccines suggests a $150-250 per dose WAC range, with peak commercial assumptions of $700-1,000M annual revenue if ACIP delivers a universal endemic-state recommendation.

Deal timeline

Related deals — scored

DealYearValueOutcome
Pfizer Inc. / Valneva SE (VLA15 collaboration update) (this deal)2022$363M
Pfizer Inc. / BioNTech SE2020$748M100
Pfizer Inc. / FoldRx Pharmaceuticals201099
Pfizer Inc. / Medivation Inc.2016$14.0B86
Pfizer Inc. / Wyeth2009$68.0B86
Pfizer Inc. / Warner-Lambert Company2000$90.0B83
Pfizer Inc. / Arvinas, Inc.2021$2.4B77

Compare all 7 side-by-side →

See the full interactive analysis, sources & comparables →